Clinical Trial Update: AB122 Platform Study [Phase 1]

View source ↗

Summary

Phase 1 AB122 platform study is currently recruiting for advanced or metastatic solid tumors, including pancreatic ductal adenocarcinoma and several other cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma
• Biliary Tract Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• AB122 Platform

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: RECRUITING